1. Home
  2. GBAB vs CCCC Comparison

GBAB vs CCCC Comparison

Compare GBAB & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest

GBAB

Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest

HOLD

Current Price

$13.81

Market Cap

396.7M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.88

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBAB
CCCC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.7M
404.7M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
GBAB
CCCC
Price
$13.81
$3.88
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.20
AVG Volume (30 Days)
104.9K
2.3M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
$13.51
$1.69
52 Week High
$15.94
$5.17

Technical Indicators

Market Signals
Indicator
GBAB
CCCC
Relative Strength Index (RSI) 44.82 51.85
Support Level $13.70 $3.40
Resistance Level $14.24 $4.49
Average True Range (ATR) 0.16 0.25
MACD -0.01 0.01
Stochastic Oscillator 20.00 51.70

Price Performance

Historical Comparison
GBAB
CCCC

About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest

Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: